Plaintiff’s work is not all profit all the time, although it can be quite lucrative. Like all entrepreneurs, plaintiff firms also make not so good investments. Some proof arises from an August 25, 2016 Global Legal Post article about a major loss for Slater & Gordon, an international plaintiff’s firm that started out in Australia,

Will insurers and analysts ever stop being surprised by the demographics and science of asbestos litigation? See below for a quote from a sell side analyst’s August 7, 2016 take on Hartford and its upsized asbestos charges, and thinking of a “more forceful” approach. It’s from Keefe, Bruyette & Woods:

“Asbestos and Environmental: Although HIG’s

Genetic testing is not a panacea for all ills. But some of the time, it produces elegantly plain evidence of the problem, and a simple cure. A very happy genetic testing story is online in an August 4, 2016 article at People.

Gathering molecular information matters. Consider the information set out in a January 7, 2016  article at europa.eu that summarizes a new medical journal on “endocrine disrupting chemicals” and  “subfertility, the inability to conceive for a prolonged period.” The summary article explains:

“The researchers measured biomarkers of EDC exposure and key fertility parameters in 163 men

What a great idea: researchers used a cohort of long-lived smokers to seek out genetic and molecular reasons for why those persons did not die young of cancer or the many other tobacco-caused diseases. They found some interesting, suggestive data but of course it’s only one step on a journey. For the basic story, see

“Patent think” continues to retrench and retrace after SCOTUS’ series of unanimous rulings that ended patents for discovery of laws of nature, and for most applications of math. A cogent summary of the rulings is provided in a July 21, 2015 blog post by John Conley at the Genomics Law Report.  Unlike some never